PF 4958242

Drug Profile

PF 4958242

Alternative Names: PF-04958242; PF-4958242

Latest Information Update: 28 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class Antipsychotics; Small molecules
  • Mechanism of Action AMPA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Schizophrenia
  • Discontinued Sensorineural hearing loss

Most Recent Events

  • 22 Sep 2016 Pfizer terminates phase II trial following an internal portfolio prioritisation in Schizophrenia in USA (NCT02855411)
  • 02 Aug 2016 PF 4958242 is still in phase I development for Schizophrenia in USA (Pfizer Pipeline,
  • 01 Aug 2016 Pfizer plans a phase II trial for Schizophrenia in USA (PO, Capsule) (NCT02855411)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top